Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Phase II, Multicentre; Randomised, Dose-finding, Double-blind and Placebo Controlled Superiority Study With Parallel Groups

Trial Profile

Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Phase II, Multicentre; Randomised, Dose-finding, Double-blind and Placebo Controlled Superiority Study With Parallel Groups

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs PR 15 (Primary)
  • Indications Carotid stenosis; Embolism and thrombosis; Stroke; Transient ischaemic attacks
  • Focus Therapeutic Use
  • Sponsors advanceCor
  • Most Recent Events

    • 15 Sep 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
    • 15 Sep 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
    • 12 Mar 2014 New source identified and integrated (UK Clinical Trials Register; UKCRN- 15606).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top